[{"abstract": "Pfizer has abandoned its bid for AstraZeneca. | N.Y.U.\u2019s trustees are tied to the university\u2019s crisis in Abu Dhabi. | The S.E.C. and private equity. | Bill Gates has cut the pace of his own giving to his foundation.", "web_url": "https://dealbook.nytimes.com/2014/05/27/morning-agenda-pfizer-lets-astrazeneca-go/", "snippet": "Pfizer has abandoned its bid for AstraZeneca. | N.Y.U.\u2019s trustees are tied to the university\u2019s crisis in Abu Dhabi. | The S.E.C. and private equity. | Bill Gates has cut the pace of his own giving to his foundation.", "lead_paragraph": "Pfizer said on Monday that it had abandoned its bid for AstraZeneca, bringing an end to a monthslong takeover effort that would have created the world\u2019s largest drug company, Jenny Anderson writes in DealBook. The decision \u2012 made on the final day for Pfizer to decide whether to abandon the deal \u2012 came in the wake of AstraZeneca\u2019s rejection of what Pfizer called its final offer earlier this month. The cash-and-stock bid valued AstraZeneca at about $119 billion.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer Lets AstraZeneca Go", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-05-27T12:03:57+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Sydney Ember", "person": [{"firstname": "Sydney", "middlename": null, "lastname": "Ember", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4c56c105-9ece-55ad-97b0-d7eff25d9cd3", "word_count": 1997, "uri": "nyt://article/4c56c105-9ece-55ad-97b0-d7eff25d9cd3"}, {"abstract": "Pfizer looks foolish for the way it handled a $119 billion bid, yet it is AstraZeneca that remains under pressure, Christopher Hughes of Reuters Breakingviews writes.", "web_url": "https://dealbook.nytimes.com/2014/05/27/the-lessons-of-a-failed-drug-deal/", "snippet": "Pfizer looks foolish for the way it handled a $119 billion bid, yet it is AstraZeneca that remains under pressure, Christopher Hughes of Reuters Breakingviews writes.", "lead_paragraph": "The failure of Pfizer\u2019s $119 billion bid for AstraZeneca leaves the frustrated buyer no worse off. But AstraZeneca has much to prove. Some of its shareholders welcomed a possible takeover \u2013 and could again.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg", "height": 900, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 900}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg", "height": 1024, "width": 683, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg", "height": 2048, "width": 1366, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "The Lessons of a Drug Maker\u2019s Failed Deal", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 5, "major": "N"}], "pub_date": "2014-05-27T15:49:36+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Christopher Hughes", "person": [{"firstname": "Christopher", "middlename": null, "lastname": "Hughes", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/673a4161-a3dd-5c7c-b644-091be9e918ff", "word_count": 343, "uri": "nyt://article/673a4161-a3dd-5c7c-b644-091be9e918ff"}]